Introduction
Natural killer (NK)-cell malignancies are a distinct disease entity, categorized as extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in the World Health Organization (WHO) classification scheme. 1, 2 Clinically, NK-cell malignancies can be divided into nasal, non-nasal and aggressive lymphoma/leukemia subtypes. [3] [4] [5] Epidemiologically, NK-cell malignancies show a predilection for Asian and South American countries, being reported mostly in the Chinese, Japanese, Korean, Mexican and Peruvian people, and are extremely uncommon in the Western populations. [3] [4] [5] Another interesting observation is the almost invariable association with EBV infection in the neoplastic NK cells.
1,2

Clinical features of NK-cell lymphomas
Nasal NK-cell lymphomas refer to tumors occurring in the nose and the upper aerodigestive tract, typically involving the nasal cavity, nasopharynx, paranasal sinuses, tonsils, hypopharynx and larynx. 3, 4, 6 Most nasal NK-cell lymphomas present as stage I/II disease, although systemic spread to the skin, gastrointestinal tract, liver, spleen and testis also occurs in advanced stages. 3, 4 Non-nasal NK-cell lymphomas may involve any part of the body, the predominant sites also being where the nasal NK-cell lymphomas disseminate to. 7 Non-nasal NK-cell lymphomas are advanced at presentation, and true-stage I/II diseases are exceptional. Nodal involvement in nasal and non-nasal NK-cell lymphomas are unusual. 8 Aggressive NK-cell lymphoma/leukemia is a catastrophic disease. [3] [4] [5] Patients are severely ill with high fever, jaundice, lymphadenopathy, hepatosplenomegaly, skin infiltration and disseminated intravascular coagulopathy. A leukemic phase may occur. The clinical progression is inexorable, with survivals often measured just in weeks. 9, 10 Radiotherapy for NK-cell lymphomas Radiotherapy is an important treatment for stage I/II nasal NK-cell lymphomas, with the overall response rates ranging from 60 to 80%, CR rates from 40 to 80% and 5-year OS from 40 to 59%. [11] [12] [13] [14] [15] [16] [17] Despite the high response rates, a median of 50% (17-77%) of cases relapse. 11, 14, 15 About half of the relapses are a result of in-field failure due to insufficient doses (o45-50 Gy) or inadequate planning. 11, 14, 15 The other half presents with systemic failures, indicating lymphoma dissemination in many apparently early-stage diseases. Therefore, stage I/II patients without contraindications to chemotherapy should receive combined chemotherapy and radiotherapy. [3] [4] [5] Chemotherapy for NK-cell lymphomas Chemotherapy is the mainstay of treatment for stage III/IV nasal NK-cell lymphoma, non-nasal NK-cell lymphoma and aggressive NK-cell lymphoma/leukemia. Chemotherapy is also advocated for stage I/II disease, owing to high relapse rates after radiotherapy.
In nasal NK-cell lymphomas, primary chemotherapy for stage I/II disease gives CR rates of 40-60%. 3, 9, 13, 15, 18 About a third of these patients relapse, so that the failure rate of chemotherapy reaches 50%. 15, 18 For stage III/IV nasal NK-cell lymphomas, non-nasal NK-cell lymphomas and aggressive NK-cell lymphoma/leukemia, CR rates are poor at B20%. 10, 19 Several reasons account for the unsatisfactory response to chemotherapy in NK-cell lymphomas. First, anthracycline-containing regimens are not superior to non-anthracycline-containing regimens. 18, 20 Second, NK cells express the highest concentrations of P-glycoprotein, because of overexpression of the multidrug resistance-1 (MDR-1) gene. 21 This phenomenon is recapitulated in NK-cell lymphomas, 22 so that anthracyclines, which are P-glycoprotein substrates, are not particularly effective. Finally, disseminated NK-cell lymphomas and aggressive NK-cell lymphoma/leukemia are often associated with organ failures and poor performance status. Systemic chemotherapy in these patients results in significant mortality, usually related to infective complications. 9, 10, 19 High-dose chemotherapy with HSCT The poor treatment results for advanced and disseminated NK-cell lymphomas lead to the use of high-dose chemotherapy with hematopoietic SCT (HSCT) to improve the outcome. As NK-cell lymphomas are uncommon even in the Asian and South American populations, controlled trials of HSCT have not been performed. The use of HSCT needs to be critically reappraised to define its role in NKcell lymphomas, and to provide leads for further research.
Review strategy
English publications indexed in the Medline were searched with the keywords NK-cell lymphomas, NK-cell leukemia, allogeneic, autologous, BMT, and HSCT. Articles with complete patient demographics, diagnosis, types of HSCT, outcome and survival were reviewed. References in reviewed articles were also scrutinized to ensure that relevant articles were included.
Patients
Natural killer-cell malignancies were defined according to the WHO classification.
1,2 Three types of lymphomas, often confused with NK-cell lymphomas in some of the series reviewed, were excluded from the analysis. These included peripheral T-cell lymphomas, angiocentric lymphomas (REAL classification), 23 and blastic NK-cell lymphomas (classified as blastic plasmacytoid DC neoplasm in the current WHO classification). 24 These tumors can readily be distinguished from NK-cell lymphomas by the absence of EBV infection and lack of expression of cytotoxic molecules and CD56.
Statistical analysis
Categorical data were analyzed by w 2 -test, and continuous data by one-way analysis of variance or t-test. The impact of potential prognostic factors, including gender, age, clinical subtypes of NK-cell lymphoma, initial disease stages and status at HSCT, on outcome was assessed by logistic regression analysis, and on OS by Cox regression analysis. Survival curves were plotted by the KaplanMeier method.
Results
Autologous HSCT
Fifty-seven patients with NK-cell malignancies who had undergone high-dose chemotherapy and autologous HSCT were identified from the literature (Table 1) . [25] [26] [27] [28] [29] [30] [31] [32] The male/ female ratio was 1.9:1, with a median age of 42 (16-67) years. There was a predominance of nasal NK-cell lymphomas (51 of 57, 89% of cases). At initial diagnosis, 63% (36 of 57) of patients had early-stage (I/II) diseases, and 37% (21 of 57) had advanced (III/IV) diseases. At the Table 1 Clinical features and treatment outcome of 57 patients with natural killer-cell malignancies undergoing high-dose chemotherapy and autologous haematopoietic SCT (HSCT)
Clinical characteristics
No. Outcome and prognostic factors of autologous HSCT At the time of reporting, 51% (29 of 57) of patients were still in remission after autologous HSCT. Other patients were either alive with disease (9 of 57, 16%), or dead from disease relapse or progression (19 of 57, 33%). Relevant data for statistical analysis were available in all reviewed cases. Of the potential prognostic factors analyzed, including gender, age, clinical subtypes of NK-cell lymphoma, initial stage and status pre-HSCT, only the status pre-HSCT was significantly related to survival after HSCT (Table 2) . Logistic regression analysis also showed that the status pre-HSCT was the only factor affecting outcome after HSCT (Po0.001; odds ratio: 2.137, 95% confidence interval: 1.352-3.380). Cox regression confirmed that the status at HSCT significantly affected OS (Po0.001; odds ratio: 1.741, 95% confidence interval: 1.351-2.244). The impact of pre-HSCT status on OS was shown in Figure 1 . The survival of patients with refractory and untreated relapses was significantly inferior to patients transplanted in CR1 and CR2.
Allogeneic HSCT Thirty-two patients with NK-cell malignancies undergoing allogeneic HSCT were identified, of whom 28 were reported in a single series, and four as case reports (Table 3) . 26, [33] [34] [35] [36] There were more female patients, and the median age was 38 (12-54) years. At the time of HSCT, 31% (10 of 32) of patients were in remission without disease, and 69% (22 of 32) of patients had residual or refractory diseases. The donors were HLA-identical siblings in 26 cases. All but five patients received myeloablative conditioning regimens.
Outcome and prognostic factors of allogeneic HSCT At the time of reporting, 16 (50%) of 32 patients were alive. Death was due to HSCT-related complications in eight patients (25%) and disease progression in another eight patients (25%). For the main series of 28 patients, the 2-year OS was 40%. 36 Gender, initial stage of disease, status at HSCT, conditioning regimen and GVHD had not been found to affect survival. In all, 19 of 28 patients had active disease at the time of allogeneic HSCT, with 32% of them achieving long-term PFS after HSCT. The only significant prognostic factor affecting PFS was age o40 years.
Discussion
The experience of HSCT in NK-cell lymphomas is limited. Except one series of autologous HSCT that studied consecutively transplanted patients, 29 all other series or case reports described patients from multiple centers, with the inclusion criteria undefined. Consequently, a heavy selection bias would have existed. Some studies had short follow-up durations, and long-term results were not available. In patients described in isolated case reports, a reporting bias toward successful treatment outcome was apparent. Finally, as none of the studies were controlled, the outcome of comparable patients treated with conventional chemotherapy and radiotherapy was not available to judge whether HSCT had affected the outcome.
Patients undergoing autologous HSCT reviewed herein showed features comparable with most case series of NK-cell lymphomas, including a male preponderance, median age of presentation in the late 40s and nasal area as the predominant primary site of involvement. [3] [4] [5] However, more patients undergoing autologous HSCT (37%) had advanced-stage (III/IV) disease at presentation, as opposed to 16-20% in reported series of NK-cell lymphoma patients. 19, 20 Multivariate analysis showed that the status pre-HSCT was the only significant factor affecting OS. The best survival after autologous HSCT occurred in patients in remission (CR1 and CR2) at the time of transplantation. The indications of HSCT at CR1 were not clearly stated in most of the reports reviewed. More than half of these patients in fact had early-stage (I and II) diseases. As most of these patients would be expected to have durable remissions with combined chemotherapy and radiotherapy, a definite advantage of autologous HSCT at CR1 is not apparent. This is particularly relevant to stage I/II patients in CR1, who have a good prognosis in general. 4 There is some evidence that autologous HSCT might be beneficial to a subgroup of patients in CR who had a high risk of relapse, as determined by prognostic modeling. 37 However, the number of cases analyzed by this prognostic model was small. Therefore, with the available evidence, stage I/II NK-cell lymphoma patients in CR1 should not be offered autologous HSCT unless in a trial setting.
For patients with relapsed disease achieving CR2 after chemotherapy ± radiotherapy, no data on their survival without additional therapy are available from the literature. Therefore, it is not possible to conclude whether autologous HSCT offers survival advantage. However, as HSCT is in general indicated for lymphoma patients in CR2, future controlled studies should be conducted to verify whether NK-cell lymphoma patients will benefit from this treatment.
Autologous HSCT in patients with advanced, active or refractory disease had a dismal outcome. The conditioning regimens used were those designed for B-cell lymphomas. It is unclear whether NK-cell lymphomas would respond optimally to such regimens. In fact, no survival was reported for NK-cell lymphoma patients transplanted with untreated relapses. Hence, there is no evidence to suggest that autologous HSCT is beneficial to NK-cell lymphoma patients with uncontrolled disease. These patients should be considered candidates for experimental protocols.
Data on allogeneic HSCT in NK-cell lymphomas are even more limited. The patients reviewed here showed a female preponderance, younger age and more advanced stages at presentation. These features were all different from typical series of NK-cell lymphoma patients, 4, 7, 9, 12 indicating considerable selection bias in patients receiving allogeneic HSCT. Similar to autologous HSCT, the multidrug resistance phenotype and the lack of specific conditioning regimens also limit the efficacy of allogeneic HSCT. A putative graft-versus-lymphoma effect may overcome these problems. This is especially plausible for NK-cell lymphoma, because the expression of EBV-related antigens 3, 4 on the lymphoma cells may conceivably enhance alloreactivity of engrafted donor-derived immunocompetent cells against neoplastic cells. However, in the current analysis, the survival of allogeneic HSCT patients was apparently similar to that of autologous HSCT patients. For autologous HSCT in CR1 and CR2 patients, OS was apparently better than in allogeneic HSCT. A similar observation was made in another study with a smaller number of patients, in which the survival of allografted patients appeared to be inferior to that of autografted patients. 31 Although patients undergoing autologous and allogeneic HSCT could not be directly compared, a significant graft-versus-lymphoma effect should improve the survival of allogeneic compared with autologous HSCT, a premise that was not substantiated by clinical observations. 31 Furthermore, typical graft-versuslymphoma effects, as evidenced by lymphoma control subsequent to the withdrawal of immunosuppression or donor lymphocyte infusion in patients relapsing after allogeneic HSCT, have not been documented. 35 Patients 440 years of age seemed to have a much inferior prognosis after allogeneic HSCT. As the median age of presentation of NK-cell lymphomas is in the fifth decade, the number of patients potentially benefiting from allogeneic HSCT is small. Hence, similar to autologous HSCT, the available data do not support the use of allogeneic HSCT in early-stage NK-cell lymphoma patients in CR. For patients with advanced or relapsed disease who achieve a CR, a survival improvement offered by allogeneic HSCT remains to be shown. For patients with refractory or uncontrolled disease, not enough data exist to show that allogeneic HSCT is beneficial. Effective conditioning regimens and a definite graft-versus-lymphoma effect are prerequisites for allogeneic HSCT to be of clear-cut benefit.
To conclude, stage I/II patients in CR1 do not benefit from frontline HSCT. For stage III/IV patients, limited data show that patients appear to have similar outcomes when transplanted in CR1 or CR2. Hence, HSCT in any form for unselected CR1 patients does not appear to be justified. However, stage III/IV patients at relapse may not necessarily achieve a CR2, which is a necessary condition for favorable HSCT outcome. Hence, identification of stage III/IV patients with a high risk of relapse may be important, so that HSCT could be carried out at CR1. Several prognostic models, including the international prognostic index, 20 modified NK prognostic model 38 and presentation plasma EBV DNA load, 39 have been found to correlate with treatment outcome in patients treated with chemotherapy and radiotherapy. Future prospective studies will be needed to investigate whether frontline HSCT for poor-risk patients identified by these prognostic models will improve outcome. As quantification of EBV DNA provides a continuous monitoring of the tumor load, it may identify minimal residual lymphoma in patients in apparent CR, 39 who may benefit from additional high-dose chemotherapy and HSCT.
For patients with persistent or residual disease, autologous or allogeneic HSCT has a poor outcome. Two strategies may improve results. Continuous efforts should be devoted to establishing a conditioning regimen effective against NK-cell lymphomas. Alternatively, innovative regimens should be considered. Recently, L-asparaginase has been found to be effective for relapsed/refractory cases. In a series of 33 cases refractory to standard chemotherapy, L-asparaginase treatment led to a CR rate of 52% and a 5-year OS of 56%. 40 L-Asparaginase was also observed to lead to apoptosis of NK lymphoma cells in vitro. 41 Finally, preliminary data of a prospective study of an L-asparaginase-containing regimen showed high efficacy against disseminated and relapsed NK-cell lymphomas. 42 Not only do these innovative regimens provide a means of achieving CR in relapsed patients, thereby rendering them potential candidates for HSCT, but also they seem to give comparable results with autologous or allogeneic HSCT for relapsed or refractory cases. It is with these considerations that future studies of the role of autologous and allogeneic HSCT in NK-cell lymphoma should be conducted.
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